← Back to Search

Antibiotic

JNJ-32729463 Open-Label for Community-acquired Pneumonia

Phase 2
Waitlist Available
Research Sponsored by Furiex Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).

Eligible Conditions
  • Community-acquired Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: JNJ-32729463 Open-LabelExperimental Treatment1 Intervention
subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
Group II: JNJ-32729463Experimental Treatment1 Intervention
Group III: moxifloxacinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-32729463
2010
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

Furiex Pharmaceuticals, IncLead Sponsor
5 Previous Clinical Trials
3,678 Total Patients Enrolled
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top